T Cell News and Research

Latest T Cell News and Research

Lipids react and change to bacterial stimulus, trigger cell's immune response

For the first time, scientists have described not only the identities and quantities of fat species in a living mammalian cell in this case, a mouse macrophage or white blood cell but they also report how these lipids react and change over time to a bacterial stimulus triggering the cell's immune response.

2 Dec 2010

Museum of Science recognizes RainDance for contributions to advance genetic research

RainDance Technologies, Inc., a private company pioneering microdroplet-based technologies for single molecule and single cell analysis, today announced that the company has been recognized by the Museum of Science, Boston and the Boston Patent Law Association for its innovations and contributions to advancing the field of genetic research.

2 Dec 2010

Baxter licenses Vero cell-based influenza vaccine technology to Takeda

Baxter International Inc. and Takeda Pharmaceutical Company Limited today announced that the parties have completed a Development, License and Technology Transfer Agreement. Under the terms of the agreement, Takeda and Baxter will expand upon their previously announced collaboration to bring Vero cell culture-based influenza vaccines to the Japanese market.

From Baxter International Inc. 2 Dec 2010

Bone marrow stromal stem cells may aid in stroke recovery: Research

A research study from the Farber Institute for Neurosciences and the Department of Neuroscience at Thomas Jefferson University determines bone marrow stromal stem cells may aid in stroke recovery. The results can be found in Cell Transplantation, The Regenerative Medicine Journal, issue 19(9).

2 Dec 2010

AMT, Amgen amend GDNF gene license agreement

Amsterdam Molecular Therapeutics Holding N.V., a leader in the development of gene-based therapies, today announced that it has amended and restated its licensing agreement with Amgen for gene therapy applications incorporating the GDNF (glial cell derived neurotrophic factor) gene, to which Amgen holds rights. Financial terms were not disclosed.

2 Dec 2010

Exposure to BPA during perinatal development impairs reproductive capacity of female offspring

Exposure to a ubiquitous environmental chemical during pregnancy may impair reproductive capacity of female offspring, according to a study published online in advance of print on December 2 in Environmental Health Perspectives. Fertility decreased over time in female mice that had been exposed during fetal and neonatal (perinatal) development to doses of bisphenol-A (BPA) that were lower than or equal to human environmental exposure levels.

2 Dec 2010

Cellectis signs agreement with Harvard Apparatus for electroporation-based instruments

Cellectis, the French genome engineering specialist, and Harvard Apparatus, a division of Harvard Bioscience, Inc. (Nasdaq: HBIO), a global developer, manufacturer, and marketer of a broad range of tools to advance life science research and regenerative medicine, have announced today that they have signed a license agreement that grants Harvard Apparatus the worldwide exclusive right to manufacture and sell, for research use, the full line of electroporation-based instruments acquired by Cellectis from CytoPulse in September of 2010.

2 Dec 2010

CytRx commences tamibarotene Phase 2b clinical trial in NSCLC

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced that it is initiating a multicenter Phase 2b clinical trial with its oncology drug candidate tamibarotene in combination with chemotherapeutical agents for the treatment of patients with advanced non-small-cell lung cancer (NSCLC).

2 Dec 2010

More effective treatment for severe form of influenza

Flu season is upon us and while getting the nasty bug is bad news, the good news is it's now possible to treat the severe form of the virus more effectively, according to a Ryerson University researcher. Though Canada is not expecting a pandemic flu season this winter Health Canada reports that about 4,000 to 8,000 Canadians die each year from flu-related pneumonia.

2 Dec 2010

American-style diet plays a vital role in prostate cancer, researchers say

Elevated fat and cholesterol levels found in a typical American-style diet plays an important role in the growth and spread of prostate cancer, say researchers at Thomas Jefferson University's Kimmel Cancer Center.

2 Dec 2010

Worm eggs may heal ulcerative colitis: Research

A new study involving a man who swallowed worm eggs to relieve symptoms of ulcerative colitis sheds light on how worms promote healing in the intestine. The study, published today in Science Translational Medicine, also identifies potential targets for more conventional ways of treating colitis, an inflammatory bowel disease.

2 Dec 2010

EHSI completes Celulas Genetica acquisition

Emerging Healthcare Solutions, Inc. today announced its acquisition of Celulas Genetica, a biotechnology firm based in Panama.

2 Dec 2010

New cell-based assay for reliable testing of HIV inhibitors

EASY-HIT is a new cell-based assay system for simple and reliable testing of HIV inhibitors. This system was developed under the leadership of Professor Ruth Brack-Werner at the Institute of Virology.

2 Dec 2010

Tolerx enters collaborative research agreement with Cancer Research Institute

Tolerx, Inc., a biopharmaceutical company developing novel therapies by modulating T cell activity, and the Cancer Vaccine Acceleration Fund (CVAF) a nonprofit program of the Cancer Research Institute established in partnership with the Ludwig Institute for Cancer Research today announced they entered into a collaborative research agreement to support development of Tolerx's drug candidate, TRX518, a monoclonal antibody designed to enhance the immune system by enabling T cells to more effectively attack cancer cells.

2 Dec 2010

Noncancerous cells from primary site appear to facilitate tumor growth: Study

The process of metastasis requires that cancer cells traveling from a primary tumor find a hospitable environment in which to implant themselves and grow. A new study from Massachusetts General Hospital (MGH) Cancer Center researchers finds that circulating tumor cells prepare this environment by bringing along from their original site noncancerous cells that support tumor growth. The report has been published online in PNAS Early Edition.

1 Dec 2010

Study identifies new genes responsible for early menarche

University of Minnesota School of Public Health researcher Ellen Demerath, Ph.D., is among an international group of researchers that has identified 30 new genes responsible for determining the age of sexual maturation in women. Many of these genes are also known to influence body fatness, obesity, and energy metabolism. Prior to the multi-institutional study, only four genes had been identified as contributing to the process.

1 Dec 2010

Study finds duplicated region of DNA in major depressive disorder

A large genetic study of people with major depression has found that a duplicated region of DNA on chromosome 5 predisposes people to the disorder. The gene involved plays an important role in the development of nerve cells, adding to evidence that disruptions in neurotransmission networks form a biological basis for depression.

1 Dec 2010

Researchers show an oncolytic virus switches off cancer cell survival signal

Researchers from Boston University School of Medicine (BUSM) have identified a mechanism by which specific viruses acting as oncolytic agents can enter and kill cancer cells. This finding, which is currently featured in an online edition of the Journal of Virology, could help lead to the development of more targeted treatments against many types of cancer.

1 Dec 2010

Health Canada approves VPRIV enzyme replacement therapy for type 1 Gaucher disease

Shire plc, the global specialty biopharmaceutical company, announces that Health Canada has approved VPRIV (velaglucerase alfa), an enzyme replacement therapy (ERT) for long-term use in pediatric and adult type 1 Gaucher disease.

1 Dec 2010

Pfizer to present data on hematology portfolio at ASH Annual Meeting

Pfizer said today that new data on investigational compounds in its hematology portfolio will be presented at the 52nd Annual Meeting of the American Society of Hematology (ASH) in Orlando, December 4-7.

1 Dec 2010